RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Results from the TRA•CER Trial
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 15
SP 13
OP 14
DO 10.1177/155989771115007
UL http://mdc.sagepub.com/content/11/15/13.abstract
AB The results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome [TRA•CER] trial showed that vorapaxar does not significantly improve outcomes in high-risk patients with non-ST-segment elevation acute coronary syndrome and significantly increases the risk of major bleeding, including intracranial hemorrhage.